Rick E. Winningham - 20 May 2025 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Brett A. Grimaud, Attorney-in-Fact
Issuer symbol: TBPH
Transactions as of: 20 May 2025
Net transactions value: -$145,190
Form type: 4
Filing time: 22 May 2025, 18:44:56 UTC
Previous filing: 04 Mar 2025
Next filing: 17 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Winningham Rick E	CHIEF EXECUTIVE OFFICER, Director	C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO	/s/ Brett A. Grimaud, Attorney-in-Fact	22 May 2025	0001302443

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TBPH	Ordinary Shares	Tax liability	$145,190	-15,364	-0.86%	$9.45	1,762,780	20 May 2025	Direct	F1
holding	TBPH	Ordinary Shares						3,900	20 May 2025	As Custodian
holding	TBPH	Ordinary Shares						92,567	20 May 2025	By Trust

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.